Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Idera Pharmaceutical (IDRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 65,459
  • Shares Outstanding, K 27,620
  • Annual Sales, $ 660 K
  • Annual Income, $ -59,880 K
  • 60-Month Beta 2.55
  • Price/Sales 99.72
  • Price/Cash Flow N/A
  • Price/Book 1.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.46
  • Number of Estimates 4
  • High Estimate -0.38
  • Low Estimate -0.53
  • Prior Year -0.80
  • Growth Rate Est. (year over year) +42.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.25 +14.22%
on 04/22/19
2.94 -12.58%
on 04/11/19
-0.15 (-5.51%)
since 03/22/19
3-Month
2.25 +14.22%
on 04/22/19
3.33 -22.82%
on 03/18/19
+0.24 (+10.30%)
since 01/23/19
52-Week
2.25 +14.22%
on 04/22/19
17.12 -84.99%
on 05/31/18
-9.91 (-79.41%)
since 04/23/18

Most Recent Stories

More News
Report: Developing Opportunities within World Wrestling Entertainment, Adient, Synaptics, WidePoint, Silvercrest Asset Management Group, and Idera Pharmaceuticals -- Future Expectations, Projections Moving into 2019

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of World Wrestling Entertainment, Inc....

WWE : 99.25 (+3.27%)
WYY : 0.43 (+2.67%)
ADNT : 24.74 (-3.13%)
IDRA : 2.57 (+8.44%)
SYNA : 37.43 (-0.95%)
SAMG : 14.54 (+1.68%)
Idera Pharmaceuticals Provides Corporate Update

Idera Pharmaceuticals, Inc. ("Idera") (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drugs for both oncology...

IDRA : 2.57 (+8.44%)
Idera Pharmaceuticals Presents ILLUMINATE-101 Data Demonstrating Tilsotolimod Activates Innate and Adaptive Immunity as Monotherapy in Patients with Refractory Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting

Idera Pharmaceuticals, Inc. ("Idera") (NASDAQ: IDRA), a clinical-stage biopharmaceutical company focused on the development, and ultimately the commercialization, of therapeutic drugs for both oncology...

IDRA : 2.57 (+8.44%)
Idera Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Provides Corporate Update

- ILLUMINATE-301 Enrollment on Track for Completion Q4 2019 -

IDRA : 2.57 (+8.44%)
Idera Pharmaceuticals Completes Enrollment Into the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment

- Results from the Phase 2 Expansion of ILLUMINATE-204 anticipated to be reported in the 4 Quarter of 2019 -

IDRA : 2.57 (+8.44%)
Idera Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the 37 Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 at 8:30 a.m. Pacific Time (11:30...

JPM : 113.74 (+0.12%)
IDRA : 2.57 (+8.44%)
Options Traders Expect Huge Moves in Idera Pharmaceuticals (IDRA) Stock

Investors in Idera Pharmaceuticals (IDRA) need to pay close attention to the stock based on moves in the options market lately.

IDRA : 2.57 (+8.44%)
New Research Coverage Highlights Tyson Foods, Windstream, Laredo Petroleum, Idera Pharmaceuticals, Diamondrock Hospitality, and Organovo -- Consolidated Revenues, Company Growth, and Expectations for 2018

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Tyson Foods, Inc. (NYSE:TSN),...

LPI : 3.35 (+0.60%)
IDRA : 2.57 (+8.44%)
DRH : 10.85 (+1.88%)
WIN : 0.34 (+3.12%)
ONVO : 1.01 (unch)
TSN : 74.45 (+2.20%)
Idera: 1Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Idera Pharmaceuticals Inc. (IDRA) on Wednesday reported a loss of $20.1 million in its first quarter.

IDRA : 2.57 (+8.44%)
Idera Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update

Idera Pharmaceuticals, Inc. ("Idera") (NASDAQ:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel nucleic acid-based therapeutics for...

IDRA : 2.57 (+8.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade IDRA with:

Business Summary

Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Idera's proprietary drug candidates are designed to modulate...

See More

Key Turning Points

2nd Resistance Point 2.75
1st Resistance Point 2.66
Last Price 2.57
1st Support Level 2.41
2nd Support Level 2.25

See More

52-Week High 17.12
Fibonacci 61.8% 11.44
Fibonacci 50% 9.69
Fibonacci 38.2% 7.93
Last Price 2.57
52-Week Low 2.25

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar